Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17209
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWood, Anna-
dc.contributor.authorO'Neal, David-
dc.contributor.authorFurler, John-
dc.contributor.authorEkinci, Elif I-
dc.date2018-
dc.date.accessioned2018-03-12T21:52:46Z-
dc.date.available2018-03-12T21:52:46Z-
dc.date.issued2018-02-21-
dc.identifier.citationInternal medicine journal 2018; online first: 21 February-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/17209-
dc.description.abstractThe advent of devices that can track interstitial glucose levels which are closely related to blood glucose levels on a near continuous basis has facilitated better insights into patterns of glycaemia. Continuous glucose monitoring (CGM) therefore allows for more intensive monitoring of blood glucose levels and potentially improved glycaemic control. In the context of the announcement on 1 April 2017 that the Australian Government will fund CGM monitoring for people with type 1 diabetes under the age of 21, this paper provides a review of the evidence for CGM and some of the ongoing challenges. The advent of devices that can track interstitial glucose levels which are closely related to blood glucose levels on a near continuous basis has facilitated better insights into patterns of glycaemia. Continuous glucose monitoring (CGM) therefore allows for more intensive monitoring of blood glucose levels and potentially improved glycaemic control. In the context of the announcement on 1 April 2017 that the Australian Government will fund CGM monitoring for people with type 1 diabetes under the age of 21, this paper provides a review of the evidence for CGM and some of the ongoing challenges. There is evidence that real-time CGM in type 1 diabetes improves HbA1c and hypoglycaemia, whilst in type 2 diabetes, the evidence is less robust. Initial barriers to widespread implementation of CGM included issues with accuracy and user friendliness, however, as the technology has evolved, these issues have largely improved. Ongoing barriers include cost, and weaker evidence for their benefit in certain populations such as those with type 2 diabetes and less glycaemic variability. CGM has the potential to reduce health care costs, although real world studies including cost-effectiveness analyses, are needed in this area.-
dc.language.isoeng-
dc.subjectContinuous Glucose Monitoring-
dc.subjectFlash glucose monitoring-
dc.subjecttype 1 diabetes-
dc.subjecttype 2 diabetes-
dc.titleContinuous Glucose Monitoring: a review of the evidence, opportunities for future use and ongoing challenges.-
dc.typeJournal Article-
dc.identifier.journaltitleInternal medicine journal-
dc.identifier.affiliationDepartment of Endocrinology, Austin Health, Heidelberg Repatriation Hospital, Heidelberg West, Victoria, Australia-
dc.identifier.affiliationUniversity of Melbourne Department of Medicine, St Vincent's Hospital Melbourne-
dc.identifier.affiliationDepartment of General Practice, The University of Melbourne-
dc.identifier.affiliationDepartment of Medicine, Austin Health and the University of Melbourne (Austin Campus), Parkville, Melbourne, VIC, Australia-
dc.identifier.affiliationMenzies School of Health Research, Darwin, NT, Australia-
dc.identifier.doi10.1111/imj.13770-
dc.identifier.orcidhttp://orcid.org/0000-0002-7648-8925-
dc.identifier.orcid0000-0003-2372-395X-
dc.identifier.pubmedid29464891-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.